Boc-Lys（Boc）-甘氨酸 | 120893-72-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Boc-Lys（Boc）-甘氨酸
• 英文名称: N,N'-bis(tert-butoxycarbonyl)-L-lysylglycine
• 英文别名: 2-[(2S)-2,6-bis({[(tert-butoxy)carbonyl]amino}) hexanamido]acetic acid；Boc-NH-Lys(Boc)-Gly-OH；Boc-Lys(Boc)-Gly-OH；2-[[(2S)-2,6-bis[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]amino]acetic acid
• CAS: 120893-72-3
• 化学式: C₁₈H₃₃N₃O₇
• 分子量: 403.476
• InChiKey: RDJOFHONSQXHOC-LBPRGKRZSA-N

物化性质

• 沸点：
  640.6±55.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  143
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Boc-Lys（Boc）-甘氨酸 生成 [1-[4-cyano-3-(trifluoromethyl)anilino]-3-(4-fluorophenyl)sulfonyl-2-methyl-1-oxopropan-2-yl] 2-[[2-[[(2S)-2,6-diaminohexanoyl]amino]acetyl]-methylamino]acetate
  参考文献：
  名称：

  NAGABBUSHAN, TATTANAHALLI L.;HASLANGER, MARTIN F.;CZARNIECKI, MICHAEL F.

  摘要：

  DOI：
• 作为产物：
  描述：

  Benzyl N-(Nalpha,Nepsilon-bis(t-butoxycarbonyl)-L-lysinoyl)-glycine 在 钯 氢气 、 甲醇 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以to provide acid 58 (887 mg, 99%) as a white foam的产率得到Boc-Lys（Boc）-甘氨酸
  参考文献：
  名称：

  Glycopeptide and lipoglycopeptide antibiotics with improved solubility

  摘要：

  本发明涉及与母体糖肽或脂肽糖肽抗生素具有不同离子化状态的糖肽衍生物和脂肽糖肽衍生物，并具有在生理条件下再生为母体糖肽或脂肽糖肽抗生素的能力。这些化合物可用作预防和/或治疗细菌感染的抗生素。

  公开号：

  US08901072B2

文献信息

• Stereoselective Oxidative Bioconjugation of Amino Acids and Oligopeptides to Aldehydes
  作者：Henriette N. Tobiesen、Lars A. Leth、Marc V. Iversen、Line Næsborg、Søren Bertelsen、Karl Anker Jørgensen

  DOI：10.1002/anie.202008513

  日期：2020.10.12

  stereoselective, near‐equimolar, and metal‐free oxidative bioconjugation of amino acids and oligopeptides to aldehydes is presented. Based on a newly developed organocatalytic oxidative concept, the C‐terminal and side‐chain carboxylic acid functionalities of amino acids and oligopeptides are shown to couple in a stereoselective manner to α‐branched aldehydes catalyzed by a chiral primary amine and a quinone as

  提出了氨基酸和寡肽与醛的第一个立体选择性，近等摩尔和无金属的氧化生物共轭反应。基于新近开发的有机催化氧化概念，氨基酸和寡肽的C末端和侧链羧酸官能团以立体选择性方式与手性伯胺和醌作为氧化剂催化的α-支化醛偶联。 。氧化偶合通常以高产率进行。对于天冬氨酸，根据保护策略，证明了侧链或C末端羧酸的选择性偶联。立体选择性，氧化生物共轭概念扩展到一系列寡肽，其中呈现了与羧酸官能团的偶联。通过将氧化偶联策略与点击概念合并，可获得用于进一步功能化的生物正交连接分子。已证明，新的立体中心的构型仅由有机催化剂决定。
• GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY
  申请人：Rafai Far Adel

  公开号：US20120149632A1

  公开（公告）日：2012-06-14

  The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections.

  该发明涉及糖肽和脂肽糖肽抗生素的衍生物，其具有相对于母体糖肽或脂肽糖肽抗生素的改变离子化状态，并且具有在生理条件下再生为母体糖肽或脂肽糖肽抗生素的能力。这些化合物可用作预防和/或治疗细菌感染的抗生素。
• SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION
  申请人：SHANGHAI KING-X BIOTECH CO., LTD

  公开号：US20220177511A1

  公开（公告）日：2022-06-09

  The invention provides a series of halogenated tetracyclic triterpene derivatives and their preparation and application. It is represented by the following general structural formula: R 1 is halogen, R 2 is H, and the halogen is selected from fluorine, chlorine, bromine or iodine; or R 1 and R 2 are each fluorine, and R 3 is an amine, alcohol, amino acid, peptide or phosphate linked to oxygen through an acyl group. The derivatives are relatively stable in rat whole blood through pharmacokinetic studies. The absolute bioavailability after a single intragastric administration for male and female rats was 15.6% and 28.4% respectively. The mean bioavailability was 22%. The derivatives showed better in vivo activities compared with the existing standard drugs enalapril and sacubitril valsartan sodium. Meanwhile, hydrophilic prodrugs of the tetracyclic triterpenoid derivatives in the present invention were prepared. The derivatives of the present invention can be used for preparing cardiovascular medicines.

  本发明提供了一系列卤代四环三萜衍生物及其制备和应用。其通式如下：R1为卤素，R2为氢，卤素选自氟、氯、溴或碘；或R1和R2均为氟，R3为胺、醇、氨基酸、肽或磷酸，通过酰基连接到氧。通过药代动力学研究，这些衍生物在大鼠全血中相对稳定。单次口服给雄性和雌性大鼠后的绝对生物利用度分别为15.6％和28.4％。平均生物利用度为22％。与现有标准药物依那普利和沙库巴曲钠相比，这些衍生物在体内活性更好。同时，本发明还制备了四环三萜衍生物的亲水性前药。本发明的衍生物可用于制备心血管药物。
• Binding of a hemoregulatory tetrapeptide by a bis-guanidinium crown ether
  作者：Andreas Späth、Burkhard König

  DOI：10.1016/j.tet.2010.06.024

  日期：2010.8

  A synthetic receptor for the molecular recognition of a tetrapeptide in aqueous buffer was obtained by combining a luminescent crown ether with two pyrrole-guanidinium moieties. The compound interacts with ammonium carboxylates of complementary geometry and binds the hemoregulatory peptide Ac-Ser-Asp-Lys-Pro with K=7 x 10(3) M(-1) at physiological pH. Shorter fragments and other tetrapeptides show no or significant reduced affinity. The binding of the target peptide to the functionalized crown ether is signalled by an increase of its emission intensity. (c) 2010 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of a novel 99mTc labeled 2-nitroimidazole derivative as a potential agent for imaging tumor hypoxia
  作者：Yoann Joyard、Vadim Le Joncour、Hélène Castel、Chérif Bounana Diouf、Laurent Bischoff、Cyril Papamicaël、Vincent Levacher、Pierre Vera、Pierre Bohn

  DOI：10.1016/j.bmcl.2013.05.015

  日期：2013.7

  Tumor hypoxia plays a major role in reducing the efficacy of therapeutic modalities like chemotherapy and radiation therapy in combating cancer. In order to target hypoxic tissues, a tripeptide ligand having a 2-nitroimidazole moiety, as a bioreductive species, was synthesized. The latter was radiolabeled with Tc-99m for imaging hypoxic regions of tumors and was characterized by means of its rhenium analogue. The biodistribution and scintigraphic image of the corresponding Tc-99m-complex showed accumulation in tumor and these results suggest that it could be a marker for imaging tumor hypoxia. Published by Elsevier Ltd.